New combo aims to extend life in aggressive lung cancer

NCT ID NCT04472949

Ongoing Disease control Sponsor: Swiss Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding chest radiation to the immunotherapy drug durvalumab can help people with advanced small cell lung cancer live longer without the disease getting worse. About 46 participants will first receive standard chemotherapy plus durvalumab, then those whose cancer responds will get durvalumab plus chest radiation for up to 2 years. The goal is to improve outcomes in a cancer that often returns quickly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER SMALL CELL LUNG CANCER

Contacts and locations

Locations

HFR Freiburg - Kantonsspital

Villars-sur-Glâne, 1752, Switzerland
Hôpitaux Universitaires de Genève

Geneva, 1211, Switzerland
IOSI Ospedale Regionale di Bellinzona e Valli

Bellinzona, 6500, Switzerland
Inselspital Bern

Bern, 3010, Switzerland
Kantonsspital - St. Gallen

Sankt Gallen, CH-9007, Switzerland
Kantonsspital Aarau

Aarau, CH-5001, Switzerland
Kantonsspital Graubuenden

Chur, CH-7000, Switzerland
Kantonsspital Olten

Olten, CH-4600, Switzerland
Kantonsspital Winterthur

Winterthur, 8401, Switzerland
Klinik Hirslanden

Männedorf, 8708, Switzerland
Regionalspital Thun

Thun, 3600, Switzerland
Spital Männedorf

Männedorf, 8708, Switzerland
Universitaetsspital Basel

Basel, 4031, Switzerland
UniversitätsSpital Zürich

Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.